IL1B and cryopyrin-associated periodic syndrome: A total of 10 out of 36 CAPS patients (28%)—including 5/6 with severe and 5/30 with moderate phenotype—required anti-IL-1 therapy escalation due to progression of sensorineural hearing loss.